EPHA2 and cancer: Our analyses indicate that higher EphA2 expression are associated with significantly worse 5‐year survival rates in OS (Figure 1A) and RMS patients (Figure 1B) as compared to patients with lower EphA2 expression, suggesting that this receptor is a promising target for therapeutic intervention in these cancers.